Bolstering Public Health Preparedness by Investing in Post-Market Incentives for Novel Antibiotics

Durg-resistant infections and antimicrobial resistance (AMR) threaten global public health, and access to innovative, novel antibiotics is critical to prepare for future health emergencies.

On October 23rd, 2023, Duke-Margolis published “Bolstering Public Health Preparedness by Investing in Post-Market Incentives for Novel Antibiotics” to describe opportunities for policymakers to establish pull incentives for novel antibiotics that advance public health preparedness and the bioindustrial base.

Key Points

• Investments in post-market incentives for novel antibiotics represent investments in public health preparedness.
• Until proposals to prevent viral pandemics and bolster public health preparedness are aligned with related efforts to combat antibiotic resistant bacteria, the United States will remain at risk.
• Policymakers can support pharmaceutical manufacturing and supply chains, surveillance systems, post-market evidence development infrastructure, and diagnostic capabilities in a manner that reduces post-market costs for the smaller novel antibiotic developers who conduct the majority of current antibiotic research and development.